266748 20250127091812.0 10.1055/a-2119-5574 doi pmid:37467779 pmid 0367-2239 ISSN 0015-8151 ISSN 1438-9029 ISSN 0340-1618 ISSN 0936-6652 ISSN 1433-5972 ISSN 1438-9010 ISSN altmetric:151730322 altmetric DZNE-2024-00011 English 610 Sollmann, Nico 0000-0002-8120-2223 0 Arterial Spin Labeling (ASL) in der neuroradiologischen Diagnostik – Methodischer Überblick und Anwendungsfälle. Stuttgart [u.a.] 2024 Thieme article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1705483494_18420 PUB:(DE-HGF) Review Article ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote Arterial spin labeling (ASL) is a magnetic resonance imaging (MRI)-based technique using labeled blood-water of the brain-feeding arteries as an endogenous tracer to derive information about brain perfusion. It enables the assessment of cerebral blood flow (CBF).This review aims to provide a methodological and technical overview of ASL techniques, and to give examples of clinical use cases for various diseases affecting the central nervous system (CNS). There is a special focus on recent developments including super-selective ASL (ssASL) and time-resolved ASL-based magnetic resonance angiography (MRA) and on diseases commonly not leading to characteristic alterations on conventional structural MRI (e. g., concussion or migraine).ASL-derived CBF may represent a clinically relevant parameter in various pathologies such as cerebrovascular diseases, neoplasms, or neurodegenerative diseases. Furthermore, ASL has also been used to investigate CBF in mild traumatic brain injury or migraine, potentially leading to the establishment of imaging-based biomarkers. Recent advances made possible the acquisition of ssASL by selective labeling of single brain-feeding arteries, enabling spatial perfusion territory mapping dependent on blood flow of a specific preselected artery. Furthermore, ASL-based MRA has been introduced, providing time-resolved delineation of single intracranial vessels.Perfusion imaging by ASL has shown promise in various diseases of the CNS. Given that ASL does not require intravenous administration of a gadolinium-based contrast agent, it may be of particular interest for investigations in pediatric cohorts, patients with impaired kidney function, patients with relevant allergies, or patients that undergo serial MRI for clinical indications such as disease monitoring.· ASL is an MRI technique that uses labeled blood-water as an endogenous tracer for brain perfusion imaging.. · It allows the assessment of CBF without the need for administration of a gadolinium-based contrast agent.. · CBF quantification by ASL has been used in several pathologies including brain tumors or neurodegenerative diseases.. · Vessel-selective ASL methods can provide brain perfusion territory mapping in cerebrovascular diseases.. · ASL may be of particular interest in patient cohorts with caveats concerning gadolinium administration.. 353 - Clinical and Health Care Research (POF4-353) G:(DE-HGF)POF4-353 POF4-353 POF IV 0 Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de Contrast Media NLM Chemicals Spin Labels NLM Chemicals Gadolinium AU0V1LM3JT NLM Chemicals Water 059QF0KO0R NLM Chemicals Humans MeSH Child MeSH Contrast Media MeSH Spin Labels MeSH Gadolinium MeSH Magnetic Resonance Imaging: methods MeSH Arteries MeSH Magnetic Resonance Angiography: methods MeSH Cerebrovascular Disorders: diagnostic imaging MeSH Migraine Disorders MeSH Water MeSH Neurodegenerative Diseases MeSH Hoffmann, Gabriel 1 Schramm, Severin 2 Reichert, Miriam 3 Hernandez Petzsche, Moritz 4 Strobel, Joachim 5 Nigris, Lorenzo 6 Kloth, Christopher 7 Rosskopf, Johannes 0000-0002-9037-5660 8 Börner, Corinna 9 Bonfert, Michaela 10 Berndt, Maria 11 Grön, Georg 12 Müller, Hans-Peter 13 Kassubek, Jan P:(DE-2719)9001967 14 dzne Kreiser, Kornelia 15 Koerte, Inga K 16 Liebl, Hans 17 Beer, Ambros 18 Zimmer, Claus 19 Beer, Meinrad 20 Kaczmarz, Stephan 21 10.1055/a-2119-5574 Vol. 196, no. 1, p. 36 - 51 PERI:(DE-600)2031079-1 1 36 - 51 RöFo 196 2024 0367-2239 http://pub.dzne.de/record/266748/files/DZNE-2024-00011_Restricted.pdf http://pub.dzne.de/record/266748/files/DZNE-2024-00011_Restricted.pdf?subformat=pdfa pdfa oai:pub.dzne.de:266748 VDB Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 14 P:(DE-2719)9001967 DE-HGF Gesundheit Neurodegenerative Diseases G:(DE-HGF)POF4-350 G:(DE-HGF)POF4-353 G:(DE-HGF)POF4 G:(DE-HGF)POF4-300 G:(DE-HGF)POF Clinical and Health Care Research 0 2024 Nationallizenz StatID:(DE-HGF)0420 StatID 2023-08-25 ger DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2023-08-25 JCR StatID:(DE-HGF)0100 StatID ROFO-FORTSCHR RONTG : 2022 2023-08-25 DBCoverage StatID:(DE-HGF)0300 StatID Medline 2023-08-25 DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2023-08-25 WoS StatID:(DE-HGF)0113 StatID Science Citation Index Expanded 2023-08-25 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2023-08-25 DBCoverage StatID:(DE-HGF)0160 StatID Essential Science Indicators 2023-08-25 DBCoverage StatID:(DE-HGF)1110 StatID Current Contents - Clinical Medicine 2023-08-25 IF < 5 StatID:(DE-HGF)9900 StatID 2023-08-25 I:(DE-2719)5000077 Clinical Study Center Ulm Clinical Study Center Ulm 0 journal VDB I:(DE-2719)5000077 UNRESTRICTED